Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
Cambridge Epigenetix, a UK-based company specializing in the development and application of epigenetic technologies, has announced the formation of its scientific advisory board (SAB) comprizing of experts in oncology, liquid biopsy and aging. 7 March 2017
Pharmaceutical
The chance to focus on an area of massive unmet medical need was a major factor in attracting Gabriel Baertschi to leave his previous role as president and general manager of AstraZeneca in Japan to take the top job at Germany’s Grünenthal Group. 7 March 2017
Pharmaceutical
In an expert view piece, Dana Shears, eMDI business development director of H&T Presspart and Melissa Manice, chief executive and co-founder of Cohero Health, look at how advances in mobile health and connected devices are opening up unprecedented opportunities in the management of chronic diseases. 7 March 2017
Pharmaceutical
Though India makes up 16% of the world's population and 20% of the world's disease burden, less than 1.4% of global clinical trials are carried out in the country. 6 March 2017
Biotechnology
USA/Israel-based biotech firm BrainStorm Cell Therapeutics has appointed Ralph Kern to the positions of chief operating and chief medical officer, effective March 6, 2017. 6 March 2017
Pharmaceutical
Trade group Medicines Australia does not accept the findings of the latest Grattan Institute report on medicine prices, calling it “inaccurate, selective and misleading.” 6 March 2017
Pharmaceutical
Denmark-based allergy specialist ALK-Abelló has appointed Hendrik Nolte as senior vice president of R&D for North America and International Markets, based in the USA. 3 March 2017
Pharmaceutical
French drugmaker Ipsen has appointed Benoit Hennion as executive vice president and president of primary care. 2 March 2017
Pharmaceutical
“A focused strategy but one that’s diverse within the areas of focus that we have” sums up the approach of Bayer and Robert LaCaze in oncology as they set their sights on making a big difference in this highly competitive and rapidly evolving environment. 2 March 2017
Pharmaceutical
Investors in Ireland-incorporated Perrigo probably did not know where to turn on Monday and Tuesday amid news on the company’s management, job cuts, divestment of royalty payment rights on a multiple sclerosis drug and its publication of bleak financial guidance. 1 March 2017
Pharmaceutical
Jakob Riis, executive vice president, head of North America Operations and president of Novo Nordisk Inc, has resigned, Danish diabetes care giant Novo Nordisk announced this morning. 1 March 2017
Pharmaceutical
In an expert view piece, CPA Global, the intellectual property (IP) management company, asks what role IP management will play in protecting pharmaceutical companies in the future? 28 February 2017
Biotechnology
Ovid’s metamorphosis from fledgling biotech startup to global rare disease specialist with epic ambitions began just two years ago with $5 million in venture capital. Now guiding the process is chief executive Jeremy Levin, who spoke to The Pharma Letter from the company’s New York headquarters about Ovid’s recent partnership with Japan’s largest drugmaker Takeda Pharmaceutical, a firm with $16 billion in revenue and some 30,000 employees. 28 February 2017
Biotechnology
Historically, we have seen combination therapies used to treat illnesses such as malaria, tuberculosis (TB) and AIDS. In all three of these cases, combination therapies, or ‘drug cocktails’ helped to fight the sickness more effectively than a single agent treatment, writes Lan Huang, chief executive of USA-based BeyondSpring, in an overview of this field. 27 February 2017
Pharmaceutical
Even as Panacea Biotec announced its tetravalent vaccine Easyfour-TT for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and hemophilus influenza type B (Hib), and Cipla has launched its hepatitis B vaccine, India has received a pat on the back from the World Health Organization for its advances in vaccine safety, reports The Pharma Letter’s India correspondent. 24 February 2017
Biotechnology
US biotech major Celgene Corp says that its president and chief operating officer (COO) Jacqualyn (Jackie) Fouse, has decided to retire from Celgene effective June 30, 2017. 24 February 2017
Biotechnology
US biotech PureTech Health has named Atul Pande its chief medical officer. 24 February 2017
Pharmaceutical
US pharma major Bristol-Myers Squibb has announced the appointment to the board of three new independent directors. 22 February 2017
Pharmaceutical
Investing in a corporate giving program can be hugely beneficial, not just for the communities your organization supports, but also your business. As well as giving back to society and helping to solve complex challenges, setting up a successful initiative can increase employee engagement and enhance brand reputation, writes Jo Taylor, program lead, Astellas Pharma Europe, in an expert view piece. 21 February 2017
Biotechnology
Dr Nicola Davies looks at some of the latest updates in an area of oncology research with considerable potential and risk. 20 February 2017
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze